Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/9868
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWilloughby, S.en
dc.contributor.authorStewart, S.en
dc.contributor.authorChirkov, Y.en
dc.contributor.authorKennedy, J.en
dc.contributor.authorHolmes, A.en
dc.contributor.authorHorowitz, J.en
dc.date.issued2002en
dc.identifier.citationEuropean Heart Journal, 2002; 23(24):1946-1954en
dc.identifier.issn0195-668Xen
dc.identifier.issn1522-9645en
dc.identifier.urihttp://hdl.handle.net/2440/9868-
dc.description© 2007 European Society of Cardiologyen
dc.description.abstractAIMS:To examine whether the prophylactic antianginal agent perhexiline potentiates platelet responsiveness to nitric oxide (NO) in patients with stable angina pectoris (SAP) and acute coronary syndromes (ACS: unstable angina pectoris or non-Q-wave myocardial infarction). METHODS AND RESULTS:Blood samples were obtained from patients before and after initiation of treatment with perhexiline. ADP-induced platelet aggregation and its inhibition by the NO donor sodium nitroprusside (SNP) were determined via impedance aggregometry in whole blood (WB) and platelet-rich plasma (PRP). Intraplatelet cGMP content was assayed by RIA, and superoxide (O(2)(-)) level by lucigenin-derived chemiluminescence. In patients with ACS not receiving perhexiline (n=12), platelet responsiveness to SNP did not vary significantly over the first 3 days post admission to hospital. Therapy with perhexiline for 3 days was associated with increases in SNP-induced inhibition of aggregation from 29+/-2% to 43+/-4% (n=50,P <0.001) in WB and from 20+/-5% to 42+/-7% (n=12, P<0.01) in PRP. Resolution of symptomatic ischaemia (n=39) was associated with significantly greater (P<0.01) increases than non-resolution (n=11). Similar increases in SNP responsiveness (P<0.001) occurred following institution of perhexiline therapy in patients with SAP (n=30), associated with a 85% decrease in anginal frequency. Treatment with perhexiline potentiated the cGMP-elevating effects of SNP in platelets (n=9,P =0.03). Although perhexiline did not alter whole blood O(2)(-) concentration ex vivo, it inhibited (P<0.01) O(2)(-) release from neutrophils in vitro. CONCLUSION:Perhexiline potentiates platelet responsiveness to NO both in SAP and ACS patients; in the latter group this improvement was predictive of resolution of ischaemic symptoms. The predominant mechanism of perhexiline effect is an increase in platelet cGMP responsiveness. Perhexiline also may reduce the potential for NO clearance by neutrophil-derived O(2)(-).en
dc.description.statementofresponsibilityS.R. Willoughby, S. Stewart, Y.Y. Chirkov, J.A. Kennedy, A.S. Holmes, and J.D. Horowitzen
dc.language.isoenen
dc.publisherW B Saunders Co Ltden
dc.subjectangina; perhexiline; nitric oxide; cGMP; plateletsen
dc.titleBeneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxideen
dc.typeJournal articleen
dc.identifier.rmid0020021370en
dc.identifier.doi10.1053/euhj.2002.3296en
dc.identifier.pubid59848-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidStewart, S. [0000-0001-9032-8998]en
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.